Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA.

Merck (NYSE:MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck is going all-in on domestic drug manufacturing with a $1 billion Delaware facility aimed at dodging Trump-era tariff ...

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the American Association for Cancer Research, Verily’s Parkinson’s dataset, the ...

The company expects labs at the new facility to be fully operational by 2028 and produce experimental drugs by 2030 ...